-
Stocks steady after tech rout, Brent falls below $75
-
'You have to work': Riders brave Rome heat for survival
-
England captain Stokes 'man enough' to apologise for curfew breach
-
France detects first Ebola case outside Africa in current outbreak
-
England captain Stokes 'man enough' to apologise after curfew breach
-
'GTA VI' preorders mark first test for biggest game of 2026
-
German naval ambitions suffer setback as warship order axed
-
Stocks rebound after tech rout, oil prices drop
-
London police to extend use of live facial recognition, drones
-
Australia spy chief warns of Iran terror threat
-
Europe swelters under record-breaking heatwave
-
Heatwave-hit Europe must adapt healthcare: WHO
-
Iran says deal to end Mideast war 'declaration of US defeat'
-
Euclid telescope snaps best photo yet of Milky Way's heart
-
S.Korea chip giant SK hynix seeks $29 bn in Nasdaq listing: regulatory filing
-
French-German tank maker KNDS fires starting gun on mega-IPO
-
'Pragmatists' vs 'hardliners': Is Iran split over US deal?
-
Right-winger Fujimori poised to win Peru president runoff
-
H5 bird flu detected in second Australia state
-
Major power outage in France as Europe wilts under record heat
-
Brazil aim for last 32 as World Cup goes into hectic phase
-
Back in stork: returning birds bring joy to Croatian village
-
Necessity drives gold miners in DR Congo's Ebola epicentre
-
China premier urges AI governance to avoid 'losing control'
-
Japan PM heckled at WWII memorial
-
Colombia beat DR Congo 1-0 to reach World Cup knockouts
-
Hanoi residents mount silent protest over home demolitions
-
West Indies brace for Sri Lanka challenge as Da Silva returns
-
US Congress passes symbolic Iran war rebuke to Trump
-
Stokes urged to use curfew controversy as fuel to beat New Zealand
-
Bolivia's government is 'stoking a civil war,' ex-president Evo Morales tells AFP
-
Seoul bounces as Asian markets look to recover from rout
-
Fans in China put politics aside to cheer Japan at World Cup
-
North Korea's Kim unveils plans for 10,000-tonne warships, nuclear navy
-
Geopolitics and AI in spotlight at China's 'Summer Davos'
-
Ghosts of Gijon linger as new World Cup format encourages collusion
-
Race for robotaxi market arrives in London
-
Panama out of World Cup after defeat to Croatia
-
Moana Pasifika axed from Super Rugby after rescue talks fail
-
Wizards choose teenage talent Dybantsa with No.1 pick in NBA Draft
-
Golden Boot battle steals the show at World Cup
-
Tuchel insists England remain on course at World Cup despite Ghana draw
-
Red or green? For Brazil, the politics of World Cup kits matter
-
Bellingham rues England's 'second game fever' after Ghana draw
-
US Congress passes landmark housing affordability bill
-
Meta offers lower cost glasses as wearables competition heats up
-
Dream job: US soccer fans paid to watch every World Cup game
-
England left frustrated by Ghana in World Cup draw
-
Europe wilts under record heat as AC sales soar
-
Grieving Deschamps to miss France's final World Cup group game
Bayer sets aside more cash to deal with weedkiller woes
German pharmaceutical and agricultural chemicals giant Bayer said it had put aside an extra 1.2 billion euros ($1.4 billion) to deal with long-running US legal woes linked to a weedkiller.
It takes to 1.7 billion euros the amount set aside to deal with litigation linked to the glyphosate-based Roundup weedkiller, the German group said in a statement late Thursday.
Bayer also said it had achieved a "major settlement" with a law firm "reducing the total number of unresolved glyphosate claims to 61,000".
This means that a total of 131,000 claims had so far either been settled or deemed not eligible, it said.
The flood of legal cases in the United States relates to claims that the weedkiller causes blood cancer. Bayer says scientific studies and regulatory approvals show that the weedkiller is safe.
The Leverkusen-based group has already spent over $10 billion to settle cases.
Despite the extra provision for the legal cases, Bayer hiked its forecasts for 2025 due to a better-than-expected performance in its pharmaceuticals division.
The maker of Aspirin now expects sales of 46 to 48 billion euros this year up from a previous forecast of 45 to 47 billion.
It also predicted earnings before interest, taxes, depreciation and amortisation -- a key measure of profitability -- of 9.7 to 10.2 billion euros up from a previous forecast of 9.5 to 10 billion.
Its shares were up two percent on the blue-chip DAX index in Frankfurt Friday, while the broader index slipped 1.8 percent.
C.Kreuzer--VB